TY - JOUR
T1 - Pertussis immunisation strategies to optimise infant pertussis control
T2 - A narrative systematic review
AU - Tessier, Elise
AU - Newport, Daniel
AU - Tran, Anh
AU - Nash, Sophie G.
AU - Mensah, Anna A.
AU - Yun Wang, Tian
AU - Shantikumar, Saran
AU - Campbell, Helen
AU - Amirthalingam, Gayatri
AU - Todkill, Daniel
N1 - Publisher Copyright:
© 2023
PY - 2023/9/22
Y1 - 2023/9/22
N2 - Objective: Countries routinely offering acellular pertussis vaccine, where long-term protection is not sustained, have the challenge of selecting an optimal schedule to minimise disease among young infants. We conducted a narrative systematic review and synthesis of information to evaluate different pertussis immunisation strategies at controlling pertussis disease, hospitalisation, deaths, and vaccine effectiveness among young infants. Methods: We conducted a review of the literature on studies about the primary, booster, and/or maternal vaccination series and synthesised findings narratively. Countries offering the first three doses of vaccine within six-months of life and a booster on or before the second year or life were defined as accelerated primary and booster schedules, respectively. Countries offering primary and booster doses later were defined as extended primary and booster schedules. All search results were screened, and articles reviewed and reconciled, by two authors. The Risk of Bias in Non-randomised Studies of Intervention tool was used to evaluate the risk of bias. Findings: A total of 98 studies were included in the analyses and the following recurring themes were described: timing of vaccination, vaccine coverage, waning immunity/vaccine effectiveness, direct and indirect effectiveness, switching from an accelerated to extended schedule, impact of changes in testing. The risk of bias was generally low to moderate for most studies. Conclusion: Comparing schedules is challenging and there was insufficient evidence to that one schedule was superior to another. Countries must select a schedule that maintains high vaccine coverage and reduced the risk of delaying the delivery vaccines to protect infants.
AB - Objective: Countries routinely offering acellular pertussis vaccine, where long-term protection is not sustained, have the challenge of selecting an optimal schedule to minimise disease among young infants. We conducted a narrative systematic review and synthesis of information to evaluate different pertussis immunisation strategies at controlling pertussis disease, hospitalisation, deaths, and vaccine effectiveness among young infants. Methods: We conducted a review of the literature on studies about the primary, booster, and/or maternal vaccination series and synthesised findings narratively. Countries offering the first three doses of vaccine within six-months of life and a booster on or before the second year or life were defined as accelerated primary and booster schedules, respectively. Countries offering primary and booster doses later were defined as extended primary and booster schedules. All search results were screened, and articles reviewed and reconciled, by two authors. The Risk of Bias in Non-randomised Studies of Intervention tool was used to evaluate the risk of bias. Findings: A total of 98 studies were included in the analyses and the following recurring themes were described: timing of vaccination, vaccine coverage, waning immunity/vaccine effectiveness, direct and indirect effectiveness, switching from an accelerated to extended schedule, impact of changes in testing. The risk of bias was generally low to moderate for most studies. Conclusion: Comparing schedules is challenging and there was insufficient evidence to that one schedule was superior to another. Countries must select a schedule that maintains high vaccine coverage and reduced the risk of delaying the delivery vaccines to protect infants.
KW - Acellular
KW - Immunisation
KW - Pertussis
KW - Schedule
KW - Vaccination
KW - Whooping cough
UR - http://www.scopus.com/inward/record.url?scp=85169814612&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.08.073
DO - 10.1016/j.vaccine.2023.08.073
M3 - Review article
C2 - 37658001
AN - SCOPUS:85169814612
SN - 0264-410X
VL - 41
SP - 5957
EP - 5964
JO - Vaccine
JF - Vaccine
IS - 41
ER -